The role of pegylated liposomal doxorubicin in ovarian cancer: A meta-analysis of randomized clinical trials

Oncologist

Volumn 18, Issue 9, 2013, Pages 1022-1031

  Gibson, Jean Marie ^a   Alzghari, Saeed ^a   Ahn, Chul ^b   Trantham, Holly ^a   La Beck, Ninh M ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Carboplatin; Meta analysis; Ovarian cancer; Paclitaxel; Pegylated liposomal doxorubicin

Indexed keywords

CANFOSFAMIDE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPOTHILONE B; GEMCITABINE; OLAPARIB; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HAZARD RATIO; HISTOLOGY; HUMAN; INFECTION; META ANALYSIS; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA;

CARBOPLATIN; META-ANALYSIS; OVARIAN CANCER; PACLITAXEL; PEGYLATED LIPOSOMAL DOXORUBICIN;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84884574646     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0126     Document Type: Article

References (35)

1. Morgan RJ, Alvarez RD, Armstrong DK et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines): Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Available at http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed March 1, 2013.
2. Kim A, Ueda Y, Naka T et al. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 2012;31:14.
3. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-1329.
4. Pignata S, De Placido S, Biamonte R et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006;6:5.
5. Drummond DC, Meyer O, Hong K et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51: 691-743.
6. Thigpen T. A rational approach to the management of recurrent or persistent ovarian carcinoma. Clin Obstet Gynecol 2012;55:114-130.
7. Rakowski JA, Ahmad S, Holloway RW. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: Current concepts. Expert Rev Anticancer Ther 2012;12:31-40.
8. Wagner U, Marth C, Largillier R et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 2012;107:588-591.
9. Pignata S, Scambia G, Ferrandina G et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. J Clin Oncol 2011;29:3628-3635.
10. Bafaloukos D, Linardou H, Aravantinos G et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group study. BMC Med 2010;8:3.
11. Brundage M, Gropp M, Mefti F et al. Health-related quality of life in recurrent platinum-sensitive ovarian cancer-results from the CALYPSO trial. Ann Oncol 2012;23:2020-2027.
12. Duggan ST, Keating GM. Pegylated liposomal doxorubicin: A review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs 2011;71: 2531-2558.
13. Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8.
14. Colombo N, Kutarska E, Dimopoulos M et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or-resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012;30:3841-3847.
15. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26:890-896.
16. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
18. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-3329.
19. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions, version 5.1.0. Available at http://handbook.cochrane.org/. Updated March 2011.
20. Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:2811-2818.
21. Vergote I, Finkler NJ, Hall JB et al. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer 2010; 20:772-780.
22. Panageas KS, Ben-Porat L, Dickler MN et al. When you look matters: The effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007;99:428-432.
23. Booth CM, Eisenhauer EA. Progression-free survival: Meaningful or simply measurable? J Clin Oncol 2012;30:1030-1033.
24. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
25. Kerbel RS, Yu J, Tran J et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79-86.
26. Chanan-Khan A, Szebeni J, Savay S et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): Possible role in hypersensitivity reactions. Ann Oncol 2003;14: 1430-1437.
27. Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc 2002;23:205-208.
28. Markman M, Kennedy A, Webster K et al. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 1999; 125:427-429.
29. Doxil [product information]. Horsham, PA: Janssen Products; 2012.
30. Markman M, Kennedy A, Webster K et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999;17:1141.
31. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro Oncol 2012;14(suppl 4):iv45-iv54.
32. Jayde V, Boughton M, Blomfield P. The experience of chemotherapy-induced alopecia for Australian women with ovarian cancer. Eur J Cancer Care (Engl) 2013;22:503-512.
33. McGarvey EL, Baum LD, Pinkerton RC et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001;9:283-289.
34. Bookman MA, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419-1425.
35. Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly-(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30:372-379.